GlassScriptPhysician profile
Shirley S Donelson
NPI 1669543120
$1,663.80
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $137 · 2021: $404 · 2022: $416 · 2023: $317 · 2024: $73.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.59 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $488.15 | 2019-2023 | Creon, Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $224.65 | 2019-2024 | Gattex |
| Ironwood Pharmaceuticals, INC | $73.69 | 2019-2023 | Linzess |
| Redhill Biopharma INC. | $37.59 | 2021-2023 | Talicia |
| Nestle Healthcare Nutrition INC. | $31.34 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $29.47 | 2023-2024 | Ocaliva |
| Janssen Biotech, INC. | $24.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $22.57 | 2024 | Voquezna |
| Celgene Corporation | $22.27 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $17.13 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.06 | 2023 | Rebyota |
| Pfizer INC. | $16.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $15.95 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.48 | 2021 | |
| Merck Sharp & Dohme LLC | $13.20 | 2023 | Dificid |
| Alexion Pharmaceuticals, INC. | $12.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,479.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Donelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.